SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.
Dr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.
SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to Celdara Medical, LLC, having its principle place of business at 16 Cavendish Ct. Lebanon, NH 03766. The license agreement includes following U.S. Patents and U.S. Patent Applications:
U.S. Patent No. 9,346,875 for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,081,669; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,435,461; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
U.S. Patent No. 10,875,907 for an invention titled “Filovirus Antibody” co-owned with the Albert Einstein College of Medicine and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10; and
U.S. Patent Application No. 17/611,391 for an invention titled “Antibodies to Sudan and Ebola Virus” co-owned with the French Ministry of Defense, USAMRDC Reference Number 18-16.
